DNLI Q2 2020 Earnings — Denali Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

DNLIDenali Therapeutics Inc.

$3B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$6M+39.3% YoY

Gross Profit

$6M100.0% margin

Operating Income

-$61M-1048.0% margin

Net Income

-$59M-1004.9% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+62.2%

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$44M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$647M

Total Liabilities

$145M

Stockholders' Equity

$502M

Cash & Equivalents

$137M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$6M	$4M	+39.3%
Gross Profit	$6M	$4M	+39.3%
Operating Income	-$61M	-$63M	+2.4%
Net Income	-$59M	-$58M	-0.7%

Revenue Segments

Alzheimer's Disease Services

$3M100%